What is VisionGate?
VisionGate operates at the forefront of medical diagnostics, specializing in the rapid and non-intrusive detection of lung cancer. Leveraging a robust portfolio of 35 patents, the company employs advanced 3D cellular imaging combined with artificial intelligence to meticulously analyze sputum samples for early signs of malignancy. This innovative approach aims to significantly enhance the accuracy of cancer detection, thereby improving patient prognoses and treatment outcomes. VisionGate is dedicated to increasing public awareness regarding lung cancer screening and providing essential resources for both medical professionals and patients.
How much funding has VisionGate raised?
VisionGate has raised a total of $57.7M across 6 funding rounds:
Private Equity
$1.8M
Private Equity
$4.4M
Debt
$5.3M
Private Equity
$20M
Private Equity
$26.1M
Debt
$150K
Private Equity (2008): $1.8M, investors not publicly disclosed
Private Equity (2010): $4.4M, investors not publicly disclosed
Debt (2014): $5.3M, investors not publicly disclosed
Private Equity (2017): $20M featuring Trinnovate Ventures
Private Equity (2017): $26.1M backed by Undisclosed
Debt (2020): $150K with participation from PPP
Key Investors in VisionGate
Trinnovate Ventures
Trinnovate Ventures is an investment company focused on accelerating healthcare innovations. They invest in and develop strategic healthcare partnerships, providing capital and assets to foster the development and business incubation of healthcare solutions.
Undisclosed Investors
What's next for VisionGate?
With the recent infusion of strategic capital, VisionGate is poised for significant expansion and further development of its proprietary detection technologies. The company's focus on early-stage lung cancer, particularly for high-risk demographics, positions it to capture a substantial share of the growing diagnostic market. Future endeavors will likely involve scaling manufacturing capabilities, expanding clinical validation studies, and forging strategic partnerships within the healthcare ecosystem to broaden market penetration and solidify its leadership in innovative cancer diagnostics. The company's commitment to research and development, supported by this latest investment, signals a strong trajectory toward improving global cancer care.
See full VisionGate company page
